A California-based biotech company says it plans to build a 100,000-square-foot factory in Bedford to supply clinical trials of several drugs it is currently developing.

Ultragenyx Pharmaceutical Inc. focuses on developing treatments for rare genetic diseases. It currently has at least two drugs in clinical-stage trials.

“Our decision to build a state-of-the-art manufacturing facility is the next logical step for us as we advance our two clinical-stage programs towards Phase 3 studies” along with other products, Chief Technical Operations Officer Dennis Huang said in a statement. “Developing internal manufacturing capabilities will allow us to enhance production processes, enabling us to further optimize quality and scale and ultimately reduce the time it takes to bring our gene therapy solutions to patients.”

The planned factory will be able to support two independent manufacturing suites with capacities of 30 runs per year. Construction is slated to be completed in 2023. Ultragenyx says already controls land and development rights that could let it add an additional 86,000 square feet to the planned factory if needed.

“We are thrilled that Ultragenyx chose Bedford as the location of its new state-of-the-art bio-manufacturing facility, which further strengthens Bedford’s life science cluster,” Bedford Town Manager Sarah Stanton said in a statement. “We appreciate Ultragenyx’s significant investment in our community bringing jobs and economic benefits to Bedford and the region, and look forward to a long-term partnership with Ultragenyx.”